
Sign up to save your podcasts
Or


We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and her advice for other biotech CEOs.
We also chat about a disappointing readout from Eli Lilly's key small molecule GLP-1 candidate, setbacks in Vertex's pain business, and the story behind Replimmune's recent FDA rejection.
By STAT4.5
320320 ratings
We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and her advice for other biotech CEOs.
We also chat about a disappointing readout from Eli Lilly's key small molecule GLP-1 candidate, setbacks in Vertex's pain business, and the story behind Replimmune's recent FDA rejection.

1,982 Listeners

754 Listeners

1,107 Listeners

819 Listeners

497 Listeners

127 Listeners

6,110 Listeners

62 Listeners

87 Listeners

35 Listeners

5,596 Listeners

55 Listeners

21 Listeners

395 Listeners

15 Listeners

12 Listeners